Merck & Co., Inc. (MRK)
| Market Cap | 262.17B |
| Revenue (ttm) | 59.31B |
| Net Income (ttm) | 4.61B |
| Shares Out | 2.53B |
| EPS (ttm) | 1.80 |
| PE Ratio | 57.48 |
| Forward PE | 16.71 |
| Dividend | $3.08 (2.98%) |
| Ex-Dividend Date | Dec 14, 2023 |
| Volume | 6,717,472 |
| Open | 102.85 |
| Previous Close | 102.48 |
| Day's Range | 102.66 - 103.68 |
| 52-Week Range | 99.14 - 119.65 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 125.68 (+21.48%) |
| Earnings Date | Feb 1, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions an... [Read more]
Financial Performance
In 2022, Merck & Co.'s revenue was $59.28 billion, an increase of 21.72% compared to the previous year's $48.70 billion. Earnings were $14.52 billion, an increase of 11.27%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for MRK stock is "Strong Buy." The 12-month stock price forecast is $125.68, which is an increase of 21.48% from the latest price.
News
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck's Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Advanced Urothelial Cancer.
Merck raises quarterly dividend to 77 cents vs. 73 cents
Merck & Co. Inc. MRK said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents.
Merck Announces First-Quarter 2024 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2024 Dividend.
Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+.
Merck paying $610 million for Caraway Therapeutics
Merck & Co. Inc. MRK said Tuesday it agreed to pay up to $610 million to acquire Caraway Therapeutics, a preclinical biopharmaceutical company pursuing new approaches for the treatment of genetically ...
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference.
US FDA panel votes against Merck's chronic cough drug
The U.S. health regulator's advisers on Friday did not recommend Merck's drug for the treatment of chronic cough.
Merck's Keytruda gets approval to treat certain types of gastric cancer
Merck MRK, +0.63% said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal cancers, alongside chemotherapy. Appr...
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Chemo as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or GEJ Cancer.
US FDA staff flags concerns on Merck's chronic cough drug
U.S. Food and Drug Administration's reviewers on Wednesday flagged concerns that data on Merck's chronic cough drug might not be sufficient to prove meaningful benefit, according to documents released...
At $100 Does Merck Stock Have Room For Growth?
Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth,
Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.
The stock market is rallying after a decline in Treasury yields boosted the case for company shares.
3 S&P stocks with growth to weather a downturn
If you're looking for companies with steady profitability, cash flow and dividends, then Broadcom Inc. NASDAQ: AVGO, McCormick & Co. Inc. NYSE: MKC and Merck & Co. NYSE: MRK are worthy candidates.
WHO's new COVID guidelines see fewer patients requiring hospitalization
Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives EU CHMP Opinion for KEYTRUDA Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic BTC.
Merck to Participate in the Jefferies London Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Jefferies London Healthcare Conference.
Merck Foundation CEO and African First Ladies discussed Healthcare Capacity Building and Breaking Infertility Stigma at Africa Asia Luminary 2023
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #AfricaAsiaLuminary--Merck Foundation conducted the 10th Edition of their annual conference “Merck Foundation Africa Asia Luminary”, in India.
Dow Stocks To Trade In November
The market is due to rally through yearend. These stock selections are due to outperform the indices on both the long and short side.
Merck to Participate in the UBS BioPharma Conference
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the UBS BioPharma Conference.
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA® Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic BTC.
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy.
Investor patience tested as pharmaceutical stocks take a tumble
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor...